Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Chronic Lymphocytic Leukemia | Research article

Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

Authors: Didar Yanardag Acik, Mehmet Bankir, Filiz Alkan Baylan, Bilal Aygun

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that ELA inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of ELA. We compared serum ELABELA levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment.

Methods

Forty two untreated CLL patients and 41 healthy volunteers were included in the study. Serum ELA levels were measured by using enzyme-linked immunosorbent assay kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISA reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer’s instructions. Statistical analysis was done by Statistical Package for Social Sciences for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. ELA and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for ELA. All p-values were 2-sided with statistical significance at 0.05 alpha levels.

Results

In our study, we found that serum ELA levels were significantly higher in patients with CLL.

Conclusions

This study highlights that ELA targeting may be a potential therapeutic option for treating CLL.
Literature
1.
Redaelli A, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care. 2004;13(3):279–87.CrossRef
2.
Kipps TJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:6096.
3.
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91(9):3379–89.CrossRef
4.
Matthew S. Davids, Targeting BCL-2 in B-cell lymphomas. Blood, 31 August 2017. Volume 130, Number 9.
5.
Catherwood MA, et al. Relevance of TP53 for CLL diagnostics. J Clin Pathol 2019;0:1–4.
6.
Shin et al., Apelinergic system structure and function. Compr Physiol. Author manuscript; available in PMC 2018 December 12.
7.
Liu J, Liu M, Chen L. Regulation of apoptosis by Apelin/APJ system. Acta Biochim Biophys Sin. 2017;49(6):471–8.CrossRef
8.
Zhang Z, Yu B, Tao GZ. Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J. 2009;122:2360–5.CrossRef
9.
Xin M, Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem. 2005;280:10781–9.CrossRef
10.
Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689–701.CrossRef
11.
Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressoroncoprotein network. Trends Biochem Sci. 2002;27:462–7.CrossRef
12.
Hassan AS, Hou J, Wei W, et al. Expression of two novel transcripts in the mouse definitive endoderm. Gene Expr Patterns. 2010;10:127–34.CrossRef
13.
Chng SC, Ho L, Tian J, et al. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27:672–80.CrossRef
14.
Pauli A, Norris ML, Valen E, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014;343:1248636.CrossRef
15.
Ho L, Tan SY, Wee S, et al. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway. Cell Stem Cell. 2015;17:435–47.CrossRef
16.
Li M, Gou H, Tripathi BK, et al. An Apela RNA-containing negative feedback loop regulates p53-mediated apoptosis in embryonic stem cells. Cell Stem Cell. 2015;16:669–83.CrossRef
17.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood. 2008;111:5446–56.CrossRef
18.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–34.CrossRef
19.
Norris ML. et al. Toddler signaling regulates mesodermal cell migration downstream of Nodal signaling. Elife. 2017 Nov 9;6. pii: e22626.
20.
Yi Y, et al. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol. 2017 Dec;147(3):663–71.CrossRef
21.
Ganguly D, et al. APELA Expression in Glioma, and Its Association with Patient Survival and Tumor Grade. Pharmaceuticals (Basel). 2019;12(1).CrossRef
22.
Peng X, Li F, Wang P, et al. Apelin-13 induces MCF-7 cell proliferation and invasion via phosphorylation of ERK1/2. Int J Mol Med. 2015;36:733–8.CrossRef
23.
Lv D, Li L, Lu Q, et al. PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol. 2016;43:569–79.CrossRef
24.
Hoffmann M, Fiedor E, Ptak A. Bisphenol a and its derivatives tetrabromobisphenol a and tetrachlorobisphenol a induce apelin expression and secretion in ovarian cancer cells through a peroxisome proliferator-activated receptor gamma-dependent mechanism. Toxicol Lett. 2017;269:15–22.CrossRef
25.
Seo JY. et al. Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53. Oncotarget, 2017, Vol. 8, (No. 31), pp: 51108–51122.).
26.
Li M, et al. An Apela RNA-containing negative feedback loop regulates p53-mediated apoptosis in embryonic stem cells. Cell Stem Cell. 2015 Jun 4;16(6):669–83.CrossRef
27.
Oliner JD, et al. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016 Jun;1:6(6).
28.
Kawauchi K, et al. The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies. Anticancer Agents Med Chem. 2009;9(5):550–9e.CrossRef
29.
Yuan Shen et al. SNHG1 attenuates hnRNPC–p53 interaction. EMBO reports Vol 18, No 4, 2017.
30.
Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 2013;3(1):26–33.CrossRef
31.
Franco R, Pirozzi G, Scala S, et al. CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg. 2012;41(2):368–75.CrossRef
32.
Rodriguez-Lara V, Peña-Mirabal E, Baez-Saldaña R, et al. Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hor monal status in lung adenocarcinoma. Arch Med Res. 2014;45(2):158–69.CrossRef
33.
Wang M, et al. CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells. OncoTargets and Therapy. 2017;10:3215–24.CrossRef
34.
Droegemeier K, et al. BCL2/MDM2 inhibitor combo effective in AML. Cancer Discov. 2019;9(2):156.
Metadata
Title
Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Authors
Didar Yanardag Acik
Mehmet Bankir
Filiz Alkan Baylan
Bilal Aygun
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6325-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer

Research article

Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women

Research article

PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma

Research article

CircRNA CBL.11 suppresses cell proliferation by sponging miR-6778-5p in colorectal cancer

Research article

Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America

Research article

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits